Page 28 - RA_Centre_Paul_STRAUSS_2017

PLUS DE 90 PUBLICAtIonS

SCIEntIfIqUES DAnS DES REvUES

IntERnAtIOnALES

1. Korenbaum C ; Pierard L ; Thiery A ; Story challenges in and outside a network setting 22. Werlé F ; Dehaynin N ; Niederst C ; going adjuvant treatment by trastuzumab:
F ; Lindner v ; Lang H & al. Treatments, Out- : Soft tissue sarcomas, Eur J Surg Oncol, Jarnet D ; Gantier M ; Karamanoukian D & design of the CARDAPAC study, BMC Can-
comes, and validity of Prognostic Scores in 2017 (velten, Michel) – C al. EBT3 films, Cancer Radiother, 2017, 21, cer, 2017, 17, 425 (Pivot, Xavier) – C
Patients With Sarcomatoid Renal Cell Car- 749-758 (Meyer, Philippe) – E
cinoma: A 20-Year Single-Institution Expe- 13. Lesueur P ; Chevalier F ; Austry JB ; 33. Gligorov J ; Ataseven B ; verrill M ; De
rience. Clin Genitourin Cancer, 2017 – D Waissi W ; Burckel H ; Noël G & al. Po- 23. Garbar C ; Mascaux C ; Giustiniani J ; Laurentiis M ; Jung KH ; Azim HA & al. Sa-
ly-(ADP-ribose)-polymerase inhibitors as Merrouche Y ; Bensussan A. Chemotherapy fety and tolerability of subcutaneous trastu-
2. Sabatier R ; Diéras v ; Pivot X ; Brain E radiosensitizers: a systematic review of pre- treatment induces an increase of autophagy zumab for the adjuvant treatment of human
; Roché H ; Extra JM & al. Safety Results clinical and clinical human studies, Onco- in the luminal breast cancer cell MCF7, but epidermal growth factor receptor 2-positive
and Analysis of Eribulin Efficacy according target, 2017, 8, 69105-69124 – B not in the triple-negative MDA-MB231, Sci early breast cancer : SafeHer phase III stu-
to Previous Microtubules-Inhibitors Sensitivity Rep, 2017, 7, 7201 – B dy's primary analysis of 2573 patients, Eur
in the French Prospective Expanded Access 14. Keller A ; Doré M ; Cebula H ; Thillays J Cancer, 2017, 82, 237-246 (Petit, Thierry
Program for Heavily Pre-treated Metastatic F ; Proust F ; Darié I & al. Hypofractionated 24. Barul C ; Fayossé A ; Carton M ; Pilor- ; Pivot, Xavier)
Breast Cancer, Cancer Res Treat, 2017 – C Stereotactic Radiation Therapy to the Resec- get C ; Woronoff AS ; Stücker I & al. Occu- – B
tion Bed for Intracranial Metastases, Int J Ra- pational exposure to chlorinated solvents
3. Raharimanantsoa M ; Zingg T ; Thiery diat Oncol Biol Phys, 2017, 99, 1179-1189 and risk of head and neck cancer in men 34. Pivot X ; Fumoleau P ; Pierga JY ;
A ; Brigand C ; Delhorme JB ; Romain B. (Noël, Georges ; Antoni, Delphine) – B : a population-based case-control study in Delaloge S ; Bonnefoi H ; Bachelot T & al.
Proposal of a new preliminary scoring tool France, Environ Health, 2017, 16, 77 (vel- Superimposable outcomes for sequential
for early identification of significant blunt 15. Pivot X ; Verma S ; Fallowfield L ; Müller ten, Michel) – B and concomitant administration of adju-
bowel and mesenteric injuries in patients at V ; Lichinitser M ; Jenkins V & al. Efficacy vant trastuzumab in HER2-positive breast
risk after road traffic crashes. Eur J Trauma and safety of subcutaneous trastuzumab 25. Zanello M ; Roux A ; Ursu R ; Peeters S ; cancer : Results from the SIGNAL/PHARE
Emerg Surg, 2017 – D and intravenous trastuzumab as part of ad- Bauchet L ; Noël G & al. Recurrent glioblas- prospective cohort, Eur J Cancer, 2017, 81,
juvant therapy for HER2-positive early breast tomas in the elderly after maximal first-line 151-160 – B
4. Menvielle G ; Dugas J ; Franck JE ; Carton cancer : Final analysis of the randomised, treatment : does preserved overall condition
M ; Trétarre B ; Stücker I & al. Occupational two-cohort PrefHer study, Eur J Cancer, warrant a maximal second-line treatment? J 35. Menoux I ; Noël G ; Namer I ; Antoni
prestige trajectory and the risk of lung and 2017, 86, 82-90 – B Neurooncol, 2017, 135, 285-297 – C D. PET scan and NMR spectroscopy for the
head and neck cancer among men and differential diagnosis between brain radia-
women in France., Int J Public Health, 2017, 16. Bignon L ; Fricker JP ; Nogues C ; 26. Meyer P ; Le Pennec F ; Hui SK ; Dehay- tion necrosis and tumour recurrence after
(velten, Michel) – C Mouret-Fourme E ; Stoppa-Lyonnet D ; nin N ; Jarnet D ; Gantier M & al. Megavol- stereotactic irradiation of brain metastases:
Caron O & al. Efficacy of anthracycline/ tage 2D topographic imaging: An attractive Place in the decision tree, Cancer Radiother,
5. Keller A ; Noël G ; Antoni D. Delineation taxane-based neo-adjuvant chemotherapy alternative to megavoltage CT for the locali- 2017, 21, 389-397 – E
of the surgical bed of operated brain metas- on triple-negative breast cancer in BRCA1/ zation of breast cancer patients treated with
tases treated with adjuvant stereotactic irra- BRCA2 mutation carriers, Breast J, 2017 TomoDirect, Phys Med, 2017, 39, 33-38 – C 36. Andersson M ; López-vega JM ; Petit T
diation : A review, Cancer Radiother, 2017, (Petit, Thierry ; Pivot, Xavier) – D ; Zamagni C ; Easton v ; Kamber J & al.
21, 804-813 – E 27. Lemarchand C ; Tual S ; Levêque-Mor- Efficacy and Safety of Pertuzumab and
17. Gérard M ; Jumeau R ; Pichon B lais N ; Perrier S ; Belot A ; velten M & al. Trastuzumab Administered in a Single Infu-
6. Baldauf JJ ; Fender M ; Bergeron C ; Mar- ; Biau J ; Blais E ; Horion J & al. Hippo- Cancer incidence in the AGRICAN cohort sion Bag, Followed by vinorelbine: vELvET
rer E ; velten M ; Pradat, P & al. Cervical campus, brainstem and brain dose-volume study (2005-2011), Cancer Epidemiol, Cohort 2 Final Results, Oncologist, 2017,
morbidity in Alsace, France : results from a constraints for fractionated 3-D radiothe- 2017, 49, 175-185 – D 22, 1160-1168 – B
regional organized cervical cancer scree- rapy and for stereotactic radiation therapy
ning program, Eur J Cancer Prev, 2017 – D : Limits and perspectives, Cancer Radiother, 28. Gatta G ; Capocaccia R ; Botta L ; 37. Sledge GW ; Toi M ; Neven P ; Sohn J ;
2017, 21, 636-647 (Noël, Georges) – E Mallone S ; De Angelis R ; Ardanaz E & al. Inoue K ; Pivot X & al. MONARCH 2 : Abe-
7. Lykoudis PM ; Partelli S ; Muffatti F ; Burden and centralised treatment in Europe maciclib in Combination With Fulvestrant in
Caplin M ; Falconi M ; Fusai GK. Treat- 18. Bibault JE ; Dussart S ; Pommier P ; of rare tumours: results of RARECAREnet- Women With HR+/HER2- Advanced Breast
ment challenges in and outside a specialist Morelle M ; Huguet M ; Boisselier P & al. Cli- a population-based study, Lancet Oncol, Cancer Who Had Progressed While Recei-
network setting : Pancreatic neuroendocrine nical Outcomes of Several IMRT Techniques 2017, 18, 1022-1039 (velten, Michel) – A ving Endocrine Therapy, J Clin Oncol, 2017,
tumours, Eur J Surg Oncol, 2017, (velten, for Patients With Head and Neck Cancer: 35, 2875-2884 – A
Michel) – C A Propensity Score-Weighted Analysis, Int J 29. Emile JF ; Julié C ; Le Malicot K ; Lepage
Radiat Oncol Biol Phys, 2017, 99, 929-937 C ; Tabernero J ; Mini E & al. Prospective 38. Xhaard C ; Dumas A ; Souchard v ;
8. Ray-Coquard I ; Trama A ; Seckl MJ ; Fo- (Noël, Georges) – B validation of a lymphocyte infiltration pro- Ren Y ; Borson-Chazot F ; Sassolas G & al.
topoulou C ; Pautier P ; Pignata S & al. Rare gnostic test in stage III colon cancer patients Are dietary reports in a case-control study
ovarian tumours: Epidemiology, treatment 19. Moitry M ; Jégu J ; Averous G ; velten treated with adjuvant FOLFOX, Eur J Can- on thyroid cancer biased by risk perception
challenges in and outside a network setting. M ; Fender M ; Akladios C & al, Reporting cer, 2017, 82, 16-24 (Merrouche, Yacine) of Chernobyl fallout? Rev Epidemiol Sante
Eur J Surg Oncol, 2017 (velten, Michel) – C reactive cellular changes on smears among – B Publique, 2017, 65, 301-308 (velten,
women who undergo cervical cancer scree- Michel) – E
9. Tallet Av ; Dhermain F ; Le Rhun E ; Noël ning: results of a cohort study after seven 30. Pivot X ; Romieu G ; Fumoleau P ; Rios M
G ; Kirova YM. Combined irradiation and years of follow-up., Eur J Obstet Gynecol ; Bonnefoi H ; Bachelot T & al. Constitutional 39. Addeo P ; velten M ; Averous G ; Faitot
targeted therapy or immune checkpoint Reprod Biol, 2017, 216, 232-238 – D variants are not associated with HER2-posi- F ; Nguimpi-Tambou M ; Nappo G & al.
blockade in brain metastases : toxicities tive breast cancer : results from the SIGNAL/ Prognostic value of venous invasion in resec-
and efficacy. Ann Oncol, 2017, 28, 2962- 20. Curtit E ; Pivot X ; Henriques, J ; Paget- PHARE clinical cohort, NPJ Breast Cancer, ted T3 pancreatic adenocarcinoma : Depth
2976 – A Bailly S ; Fumoleau P ; Rios M & al, Assess- 2017, 3, 4 (Petit, Thierry) – NC of invasion matters, Surgery, 2017, 162,
ment of the prognostic role of a 94-single 31. Pivot X ; Spano JP ; Espie M ; Cottu 264-274 – B
10. Gatta G ; Trama A ; Capocaccia R. Epi- nucleotide polymorphisms risk score in early P ; Jouannaud C ; Pottier v & al. Patients''
demiology of rare cancers and inequalities breast cancer in the SIGNAL/PHARE pros- preference of trastuzumab administration 40. Delhorme JB ; Severac F ; Waissi W ;
in oncologic outcomes., Eur J Surg Oncol, pective cohort: no correlation with clinico- (subcutaneous versus intravenous) in HER2- Romain B ; Antoni D ; Freel KC & al. Surgery
2017 (velten, Michel) – C pathological characteristics and outcomes, positive metastatic breast cancer : Results Is an Effective Option after Failure of Che-
Breast Cancer Res, 2017, 19, 98 (Petit, of the randomised MetaspHer study, Eur J moradiation in Cancers of the Anal Canal
11. Jégu J ; Moitry M ; Bara S ; Trétarre B Thierry) – B Cancer, 2017, 82, 230-236 and Anal Margin, Oncology, 2017, 93,
; Guizard Av ; Woronoff AS & al. Metho- – B 183-190 (Noël, Georges) – D
dological issues of assessing the risk of a 21. Tual S ; Lemarchand C ; Boulanger M
second cancer occurring in the same site ; Dalphin JC ; Rachet B ; Marcotullio E & 32. Jacquinot Q ; Meneveau N ; Chatot M 41. Ohnleiter T ; Truntzer P ; Antoni D ; Gui-
as a first cancer using registry data, Can- al. Exposure to Farm Animals and Risk of ; Bonnetain F ; Degano B ; Bouhaddi M & hard S ; Elgard AM ; Noël G. Prognostic
cer Epidemiol, 2017, 51, 41-43 (velten, Lung Cancer in the AGRICAN Cohort, Am al. A phase 2 randomized trial to evaluate factors for head and neck cancer reirradia-
Michel) – D J Epidemiol, 2017, 186, 463-472 (velten, the impact of a supervised exercise program tion : A systematic review, Cancer Radiother,
12. Pasquali S ; Bonvalot S ; Tzanis D ; Michel) – A on cardiotoxicity at 3 months in patients with 2017, 21, 316-338 – E
Casali PG ; Trama A ; Gronchi A. Treatment HER2 overexpressing breast cancer under-

26 | Rapport annuel 2017